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In the current issue of Brain, Amin and colleagues report their investigation of the incidence 
of migraine attacks, the changes in diameter of selected extra- and intracranial arteries and the 
changes in the plasma levels of pituitary adenylate cyclase-activating polypeptide-38 
(PACAP-38) and vasoactive intestinal peptide (VIP) after the infusion of VIP and PACAP-
38. Such an investigation is essential for migraine research, because it comprises a head-to-
head comparison of the vascular and biochemical responses of these peptides with long-
lasting observations of migraine attacks. The authors reported that 73% (n=16) and 18% (n=4) 
of their patients developed migraine-like attacks after PACAP-38 and after VIP infusion, 
respectively. Three of the four patients who developed migraine-like headache after VIP 
administration also reported attacks after PACAP-38 treatment. This study elegantly 
demonstrated that PACAP-38 infusion induces more migraine headache attacks than VIP.  
VIP and PACAP-38 are potent vasodilators of cerebral and dural arteries. All three receptors 
for VIP/PACAP are present on cranial arteries. Amin et al. observed that both neuropeptides 
caused pronounced dilations of the extracranial (the superficial temporal artery, the middle 
meningeal artery, the external carotid artery and the cervical segment of the internal carotid 
artery), but not the intracranial arteries. The main difference in this effect was found to be that 
the PACAP-38-induced vasodilation was longer-lasting (> 2 h), whereas the VIP-induced 
dilatation was normalized after 2 h.  
The plasma PACAP-38 level was observed to be increased at 1 h after the start of PACAP-38 
infusion only in those patients who later reported migraine attacks. The source of the 
elevation in plasma PACAP-38 is unknown, but this finding suggests the possibility of the de 
novo synthesis or release of PACAP-38 during a migraine attack. However, the blood level of 
VIP was unaltered after the intravenous administration of PACAP-38. 
It was concluded that infused PACAP-38 induced more migraine-like attacks and much 
longer-lasting dilatation of the extracranial arteries than did VIP and the plasma PACAP-38 is 
elevated before the onset of migraine attacks (Amin et al., 2014).  
In recent years there has been considerable interest in the pathomechanism of migraine 
(Vécsei et al., 2013). Migraine, a primary form of headache, is a common, paroxysmal highly 
disabling, neurovascular disease, with a high socio-economic and personal impact. It is a very 
complex disorder, involving head pain and a wide spectrum of concomitant clinical 
symptoms. It affects more than 16% of the general population. In spite of this, its genetic 
background has not been established in detail and appropriate prophylactic and clinical 
therapy for the treatment of attacks is not available.  
In line with this study, it was earlier demonstrated that the intravenous administration of 
PACAP-38 causes headache in healthy subjects and migraine-like attacks in migraine patients 
without aura, on average 6 h after the start of the infusion (Schytz et al., 2009). It was further 
reported that PACAP-38 results in an increase in diameter of the superficial temporal arteries 
and a decrease in the mean blood flow velocity of the middle cerebral arteries (Schytz et al., 
2009; Amin et al., 2012). 
 
Connections of PACAP-38 and the trigeminovascular system 
PACAP is a member of the VIP/secretin/glucagon neuropeptide superfamily and is considered 
to be a "brain-gut peptide", by virtue of its widespread expression and functions in the human 
organism. The peptide exists in two biologically active forms: PACAP-27 and 
(predominantly), PACAP-38. It is a pleiotropic peptide: it acts as a hypophysiotropic 
hormone, a neurotransmitter and a neuromodulator in the nervous system, and it exerts 
neuroprotective, anti-apoptotic and differentiation-inducing effects in the developing nervous 
system. The effects of PACAP are mediated through G-protein-linked receptors: VPAC1, 
VPAC2 and PAC1 (Vaudry et al., 2009). 
Since the 1990s, the central theme of migraine research has been the trigeminovascular theory 
(Moskowitz, 1992). The trigeminovascular system (TS) provides an important pain-
transmission link between the vascular (dural and cortical) and neuronal (brainstem and 
thalamus) regions. The sensory trigeminal unit is controlled by the descending pathways from 
the monoaminergic nuclei, and a number of neuropeptides, such as calcitonin gene-related 
peptide (CGRP), VIP and PACAP, have essential roles in the activation mechanisms of the 
TS (Edvinsson, 2013). PACAP-38 is present in the TS, e.g. in the trigeminal ganglion (TRG) 
and caudal trigeminal nucleus (TNC) (Tajti et al., 2001).  
 
PACAP-38 and light aversion (photophobia) 
Markovics et al. investigated the pathophysiological changes induced in the TS by 
nitroglycerol (NTG) and PACAP in PACAP gene-deleted and wild-type mice. NTG is a well-
known NO donor, which causes an immediate and a delayed migraine-like attack in migraine 
patients without aura. After NTG administration, PACAP-deficient mice displayed a reduced 
level of light aversive behaviour (photophobia), and decreases in meningeal blood flow and c-
fos expression in the TRG and TNC. Moreover PACAP-38 also elicited light aversion, 
similarly to that of NTG in wild-type mice, but not in PACAP-deficient mice (Markovics et 
al., 2012). These results suggest that PACAP is an important mediator of light aversion and 
meningeal blood flow regulation.  
 
PACAP-38 and TRG activation 
Chemical (NTG) and electrical (square pulses) stimulation of the TRG in rats resulted in 
significantly elevated concentrations of PACAP-27 and -38 in the TNC. The plasma PACAP-
38-like immunoreactivity (LI) was increased following electrical stimulation (Tuka et al., 
2012). These data suggested that these peptides have marked effects of TS activation. 
 
PACAP-38 and migraine phases (interictal and ictal) 
In migraine patients in attack-free periods and during the headache phases, in migraine 
patients significantly lower PACAP-38 immunoreactivity was detected in the interictal 
plasma as compared with the healthy control group. In contrast, the PACAP-38 and CGRP 
concentrations were elevated in the ictal phase relative to the attack-free period in 21 
migraineurs, while the PACAP-38-LI was higher in the overall population of migraineurs. A 
negative correlation was observed between the interictal PACAP-38 level and the disease 
duration. Interestingly, the plasma PACAP-38 release in the ictal period was significant only 
in menstruation cycle-independent migraineurs and those patients whose had no other chronic 
pain condition, such as low-back pain, lumbago or arthrosis (Tuka et al., 2013). This study 
revealed a clear association between the migraine phases and the changes in plasma PACAP-
38 level.  
 
The results obtained by Amin et al. (Amin et al., 2014) will have a considerable scientific 
impact. Their observations are milestones as concerns the role of PACAP and the 
pathomechanism of migraine. They elegantly demonstrate the difference between PACAP-38 
and VIP-related migraine attacks, the extracranial vasodilation and the plasma concentrations 
of PACAP-38 in a head-to-head study. These findings open the way for further research to 
identify specific cause-related therapy.    
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